Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Jun 6;58(6):769.
doi: 10.3390/medicina58060769.

Predictors of Noninvasive Respiratory Support Failure in COVID-19 Patients: A Prospective Observational Study

Rolandas Zablockis  1   2 , Goda Šlekytė  1   2 , Rūta Mereškevičienė  2 , Karolina Kėvelaitienė  1   2 , Birutė Zablockienė  3   4 , Edvardas Danila  1   2
Affiliations
Observational Study

Predictors of Noninvasive Respiratory Support Failure in COVID-19 Patients: A Prospective Observational Study

Rolandas Zablockis et al. Medicina (Kaunas). .

Abstract

Background and Objective: Respiratory assistance tactic that is best for COVID-19-associated acute hypoxemic respiratory failure (AHRF) individuals has yet to be determined. Patients with AHRF may benefit from the use of a high-flow nasal cannula (HFNC) and non-invasive ventilation (NIV). The goals of this prospective observational research were to estimate predictive factors for HFNC and NIV failure in COVID-19-related AHRF subjects. Materials and Methods: The research enlisted the participation of 124 patients. A stepwise treatment approach was used. HFNC and NIV were used on 124 (100%) and 64 (51.6%) patients, respectively. Thirty (24.2%) of 124 patients were intubated and received invasive mechanical ventilation. Results: 85 (68.5%) patients were managed successfully. Patients who required NIV exhibited a higher prevalence of treatment failure (70.3% vs. 51.6%, p = 0.019) and had higher mortality (59.4% vs. 31.5%, p = 0.001) than patients who received HFNC. Using logistic regression, the respiratory rate oxygenation (ROX) index at 24 h (odds ratio (OR) = 0.74, p = 0.018) and the Charlson Comorbidity Index (CCI) (OR = 1.60, p = 0.003) were found to be predictors of HFNC efficacy. It was the ROX index at 24 h and the CCI optimum cut-off values for HFNC outcome that were 6.1 (area under the curve (AUC) = 0.73) and 2.5 (AUC = 0.68), respectively. Serum ferritin level (OR = 0.23, p = 0.041) and lymphocyte count (OR = 1.03, p = 0.01) were confirmed as predictors of NIV failure. Serum ferritin level at a cut-off value of 456.2 ng/mL (AUC = 0.67) and lymphocyte count lower than 0.70 per mm3, (AUC = 0.70) were associated with NIV failure with 70.5% sensitivity, 68.7% specificity and sensitivity of 84.1%, specificity of 56.2%, respectively. Conclusion: The ROX index at 24 h, CCI, as well as serum ferritin level, and lymphocyte count can be used as markers for HFNC and NIV failure, respectively, in SARS-CoV-2-induced AHRF patients.

Keywords: COVID-19; acute hypoxemic respiratory failure; high-flow nasal cannula; non-invasive ventilation; predictive factor.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The flow of screening and patient inclusion. AHRF: acute hypoxemic respiratory failure; HFNC: high-flow nasal cannula; NIV: non-invasive ventilation; IMV: invasive mechanical ventilation.
Figure 2
Figure 2
The ROC curves of the CCI and ROX index at 24 h for predicting HFNC failure. HFNC: high-flow nasal cannula; CCI: Charlson comorbidity index; ROX: the respiratory rate oxygenation; ROC: Receiver operator characteristic.
Figure 3
Figure 3
The ROC curves of serum ferritin level and lymphocyte count for prediction of NIV failure. NIV: non-invasive ventilation; ROC: Receiver operator characteristic.
See this image and copyright information in PMC

References

    1. Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032. - DOI - PMC - PubMed
    1. Lin L., Liu Y., Tang X., He D. The Disease Severity and Clinical Outcomes of the SARS-CoV-2 Variants of Concern. Front. Public Health. 2021;9:775224. doi: 10.3389/fpubh.2021.775224. - DOI - PMC - PubMed
    1. Xia J., Zhang Y., Ni L., Chen L., Zhou C., Gao C., Wu X., Duan J., Xie J., Guo Q., et al. High-Flow Nasal Oxygen in Coronavirus Disease 2019 Patients with Acute Hypoxemic Respiratory Failure: A Multicenter, Retrospective Cohort Study. Crit. Care Med. 2020;48:e1079–e1086. doi: 10.1097/CCM.0000000000004558. - DOI - PMC - PubMed
    1. Rorat M., Szymanski W., Jurek T., Karczewski M., Zelig J., Simon K. When Conventional Oxygen Therapy Fails-The Effectiveness of High-Flow Nasal Oxygen Therapy in Patients with Respiratory Failure in the Course of COVID-19. J. Clin. Med. 2021;10:4751. doi: 10.3390/jcm10204751. - DOI - PMC - PubMed
    1. Attaway A.H., Scheraga R.G., Bhimraj A., Biehl M., Hatipoglu U. Severe COVID-19 pneumonia: Pathogenesis and clinical management. BMJ. 2021;372:n436. doi: 10.1136/bmj.n436. - DOI - PubMed

Publication types